Skip to main content

Table 3 Primary endpoint (pneumonia) in each subgroup

From: The 23-valent pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis: a double-blinded, randomized, placebo-controlled trial

Subgroup PPSV23 Placebo P value
With rheumatoid lung 12.3% (10/81) 5.6% (4/71) 0.1534
Receiving biologics 3.1% (8/257) 2.4% (6/253) 0.6085
Receiving immunosuppressants 4.1% (3/74) 2.9% (2/70) 0.6950
Receiving steroid (>5 mg/day of prednisolone) 3.9% (5/130) 2.6% (3/117) 0.5698
With advanced stage 3.7% (9/246) 3.8% (9/239) 0.9502
  1. Data presented as percentage (number)
  2. PPSV23 23-valent pneumococcal polysaccharide vaccine